Sevoflurane: Difference between revisions
m (Protected "Sevoflurane": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
Gerald Chi (talk | contribs) m (Changed protection level for "Sevoflurane" ([Edit=Allow only autoconfirmed users] (expires 03:03, 25 June 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 03:03, 25 June 2014 (UTC)))) |
(No difference)
|
Revision as of 03:03, 11 June 2014
File:Sevoflurane2.png | |
File:Sevoflurane-3D-balls.png | |
Clinical data | |
---|---|
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C4H3F7O |
Molar mass | 200.055 g/mol |
Sevoflurane (2,2,2-trifluoro-1-[trifluoromethyl]ethyl fluoromethyl ether), also called fluoromethyl hexafluoroisopropyl ether, is a sweet-smelling, non-flammable, highly fluorinated methyl isopropyl ether used for induction and maintenance of general anesthesia. Together with desflurane, it is replacing isoflurane and halothane in modern anesthesiology. It is often administered in a mixture of nitrous oxide and oxygen. After desflurane it is the volatile anesthetic with the fastest onset and offset. Though desflurane has the lowest blood/gas coefficient of the currently used volatile anesthetics, sevoflurane is the preferred agent for mask induction due to its lesser irritation to mucous membranes.
Though it vaporizes readily, it is a liquid at room temperature and is administered via an anesthetic vaporizer attached to an anesthetic machine.
It was introduced into clinical practice initially in Japan in 1990.
Sevoflurane forms at least two degradation products, Compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] and Compound B [1,1,1,3,3-pentafluoro-2-(fluoromethoxy)-3-methoxypropane], on contact with the soda lime in a rebreathing apparatus, which absorbs exhaled carbon dioxide, especially at higher temperatures and when the soda lime is desiccated. Compound A has been shown to cause renal necrosis in rats. In humans, direct histological evidence of renal toxicity has not been demonstrated, although there is dose-related proteinuria, glycosuria and enzymuria. During low-flow anaesthesia, when the lower fresh gas flow leads to decreased flushing of the circuit and increased temperature of the soda lime, Compound A may build up to clinically significant levels. As a result, sevoflurane is sometimes administered with a minimum fresh gas flow of 2 liters per minute, making it a relatively expensive choice for maintaining general anesthesia.
Physical properties
Boiling point: | 58.6 °C | (at 101.325 kPa) | |
Density: | 1.517–1.522 g/cm³ | (at 20 °C) | |
MAC : | 2 vol % | ||
Molecular Weight: | 200 u | ||
Vapor pressure: | 157 mmHg (20.9 kPa) | (at 20 °C) | |
197 mmHg (26.3 kPa) | (at 25 °C) | ||
317 mmHg (42.3 kPa) | (at 36 °C) | ||
Blood:Gas Partition Coefficient: | 0.68 | ||
Oil:Gas Partition Coefficient: | 47 |
External links
de:Sevofluran it:Sevoflurano nl:Sevofluraan http://www.priory.com/anaesthesia/propofol_and_sevoflurane.htm Template:WikiDoc Sources
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Anesthetics
- Ethers
- Organofluorides